Display options
Cite
Curry N. Fibrinogen Replacement in Haemostatic Resuscitation: Dose, Laboratory Targets and Product Choice. Transfus Med Rev. 2021;35(4):104-107doi: 10.1016/j.tmrv.2021.06.005.
Curry, N. (2021). Fibrinogen Replacement in Haemostatic Resuscitation: Dose, Laboratory Targets and Product Choice. Transfusion medicine reviews, 35(4), 104-107. https://doi.org/10.1016/j.tmrv.2021.06.005
Curry, Nicola. "Fibrinogen Replacement in Haemostatic Resuscitation: Dose, Laboratory Targets and Product Choice." Transfusion medicine reviews vol. 35,4 (2021): 104-107. doi: https://doi.org/10.1016/j.tmrv.2021.06.005
Curry N. Fibrinogen Replacement in Haemostatic Resuscitation: Dose, Laboratory Targets and Product Choice. Transfus Med Rev. 2021 Oct;35(4):104-107. doi: 10.1016/j.tmrv.2021.06.005. Epub 2021 Aug 25. PMID: 34565636.
Copy Download .nbib Format: NLM
Share it on

Transfus Med Rev. 2021 Oct;35(4):104-107. doi: 10.1016/j.tmrv.2021.06.005. Epub 2021 Aug 25.

Fibrinogen Replacement in Haemostatic Resuscitation: Dose, Laboratory Targets and Product Choice.

Transfusion medicine reviews

Nicola Curry

Affiliations

  1. Oxford Haemophilia & Thrombosis Centre, Oxford University Hospitals NHS Foundation Trust, and Oxford University, NIHR BRC Haematology Theme, Oxford, UK. Electronic address: [email protected].

PMID: 34565636 DOI: 10.1016/j.tmrv.2021.06.005

Abstract

Fibrinogen is a key coagulation protein that is necessary for the formation of stable clots. Fibrinogen levels have been reported to be one of the first to fall during major haemorrhage reflecting consumption, dilution and fibrinogenolysis. Its role in acquired major haemorrhage, both in relation to the contribution it plays to the coagulopathy of major bleeding that can exacerbate bleeding and how effective fibrinogen supplementation can be at improving clinical outcomes, has received a great deal of attention over the last 10 - 15 years. This commentary focuses on just three of the more recent publications from the last 5 years that provide some of the evidence behind how we can think about fibrinogen as a haemostatic treatment for acquired major haemorrhage and how we can use the laboratory thresholds to guide therapy.

Copyright © 2021. Published by Elsevier Inc.

Keywords: acquired coagulopathy; cryoprecipitate; fibrinogen concentrate; major haemorrhage

Publication Types